During the second cycle of immunotherapy, the tumor blood markers CEA and CA19-9 showed an increasing trend, so the second cycle was supplemented with two oral treatments of 40 mg of S-1 per day.
← all excerpts
Advanced gallbladder cancer with high tumor mutation burden: a case report and literature review.
1
—
—